Eton Pharmaceuticals (ETON) Set to Announce Earnings on Tuesday

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) is set to issue its quarterly earnings data after the market closes on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.01) per share for the quarter. Parties interested in participating in the company's conference call can do so using this link.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.05). The business had revenue of $9.07 million for the quarter, compared to analyst estimates of $10.00 million. Eton Pharmaceuticals had a negative return on equity of 43.62% and a negative net margin of 21.31%. On average, analysts expect Eton Pharmaceuticals to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Eton Pharmaceuticals Price Performance

Shares of NASDAQ ETON remained flat at $8.67 during mid-day trading on Thursday. 109,155 shares of the stock were exchanged, compared to its average volume of 86,331. The business has a fifty day simple moving average of $6.69 and a 200-day simple moving average of $4.68. The firm has a market cap of $224.03 million, a PE ratio of -33.35 and a beta of 1.25. Eton Pharmaceuticals has a 1-year low of $3.03 and a 1-year high of $9.12.

Insider Buying and Selling at Eton Pharmaceuticals

In related news, major shareholder Opaleye Management Inc. bought 11,248 shares of the stock in a transaction on Monday, October 7th. The shares were purchased at an average price of $7.22 per share, for a total transaction of $81,210.56. Following the acquisition, the insider now owns 2,730,000 shares in the company, valued at $19,710,600. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Over the last quarter, insiders acquired 85,600 shares of company stock valued at $462,674. 14.89% of the stock is owned by company insiders.

Analyst Ratings Changes

ETON has been the topic of several recent analyst reports. HC Wainwright upped their price objective on shares of Eton Pharmaceuticals from $9.00 to $11.00 and gave the stock a "buy" rating in a report on Friday, October 4th. Craig Hallum lifted their price target on shares of Eton Pharmaceuticals from $10.00 to $15.00 and gave the stock a "buy" rating in a research note on Monday, October 28th.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.